Author: embeds

Rabies [notifiable disease]

Recent Incident: Bat contact was not recognised (effectively touching a bat without gloves means treatment is recommended)

Important: Rabies Vaccine is in short supply and we must do a UKHSA risk assessment.  Call RIgS 09:30-17:00 7 days, Info required HERE

 

Rabies is an acute viral encephalomyelitis caused by members of the lyssavirus genus. The UK has been declared “Rabies-Free”. However, it is known that even in  “Rabies-Free” counties the bat population posse a risk.

In the UK the only bat to carry rabies is the Daubenton’s Bat [Picture on the Left] and this is not a common bat in the UK. The UK and Ireland are Classified as “low-risk” for bat exposure. Despite our “low-risk” status in 2002 a man died from rabies caught in the UK from bat exposure.

Although rabies is rare it is fatal so we must treat appropriately, Public Health England – Green book details this.

Risk Assessment

To establish patients risk and thus treatment you need to establish the Exposure Category and Country Risk [Link to Country Risk]

Exposure Category

Combined Country/Animal & Exposure Risk

Treatment

Obviously patients with wounds will need appropriate wound care and cleaning, specifics for rabies are below.

If in ANY doubt, or you feel you need advice about treatment contact: On-Call Microbiologist (who will contact PHE or Virology advice)

 

You will likely need to liaise with the duty pharmacist to obtain vaccine or HRIG – which may need to be sent from a different hospital. [it is probably worth trying to obtain the 1st weeks treatment if possible, to avoid treatment delays]

IN HOURS 08:30AM-5PM PLEASE CALL PHARMACY TO INFORM THEM TO EXPECT A DELIVERY OF IMMUNOGLOBULIN SO THIS CAN BE SEGREGATED FOR THE CORRECT PATIENT. PLEASE ASK TO SPEAK TO THE RESPONSIBLE PHARMACIST                      CRH (4218/4279) HRI (2422/7123) 


UKHSA Rabies and Immunoglobulin Service (RIgS)

  • Telephone: 0330 128 1020

Routine operating hours: 09:30–17:00, seven days per week, including weekends.

All patients presenting with a possible rabies exposure should undergo an initial clinical assessment, including wound management, assessment of the exposure and previous vaccination history.

During routine hours: Contact RIgS for specialist risk assessment, advice on post-exposure vaccination and any requirement for human rabies immunoglobulin (HRIG).

Outside routine hours:

  • For the highest-risk exposures in patients who have not received their first post-exposure vaccine dose, contact the UKHSA emergency duty doctor service. These include head or neck exposures (excluding UK bat exposures under this specific criterion) and exposure to an animal confirmed to have rabies.
  • For other potential rabies exposures, administer a dose of rabies vaccine if the patient has not yet received vaccine, or if a scheduled dose is due, provided vaccine is available locally.
  • Contact RIgS after 09:30 the following day to complete the risk assessment and confirm further treatment.

All advice and administered treatment must be documented in the patient’s clinical record. Pharmacy must be informed of vaccine and HRIG administration, and arrangements made for subsequent doses.

HRIG: Indications, dosage and administration must follow the current UKHSA interim recommendations for HRIG use (June 2025), alongside the national rabies post-exposure treatment guidance.

Information required for next morning referral – HERE

 

Mitochondrial Disease

Mitochondrial diseases are a diverse group of inherited disorders characterised by dysfunction of the mitochondrial respiratory chain, resulting in impaired cellular energy production.

These conditions frequently affect multiple organ systems and can present significant challenges in the Emergency Department. Evidence to guide management remains limited, particularly for specific complications, and specialist advice is often required.

Key principles for emergency care:

Mitochondrial Disease Information

Access specialist NHS information about mitochondrial diseases, including clinical features, diagnosis and management.

View NHS Mitochondrial Disease Info

Clinical Care Guidelines

Access specialist NHS guidance for healthcare professionals on the assessment, management and ongoing care of patients with mitochondrial disease.

View NHS Clinical Care Guidelines

Hyperkalaemia

Remember: is it a haemolysed blood sample? (you can do an iSTAT)

Severity

  • Mild: 5.5-5.9mmol/l – No urgent action required (Dietary & Medication modification & GP F/U)
  • Moderate: 6.0-6.4mmol/l – Follow treatment guide (maybe suitable for discharge)
  • Severe: ≥6.5mmol/l OR ECG changes – Follow treatment guide, must admit

Read more

Myocardial Infarction (MI) – PPCI/Thrombolysis

PPCI

Target:
Door to balloon 90min

Criteria Time:
Chest pain within 12hrs (or worsened within 12hrs)

ECG: 
ST elevation MI (2 contiguous: 1mm Limb or 2mm Chest leads)
New LBBB.
(Posterior MI do posterior leads and discuss with LGI)

Actions:
Resuscitate as required
Contact PPCI team @ LGI (Mobile No. up in Resus)
Arrange blue light (P1) ambulance to LGI

Medication:
Prasagrel 60mg if – no previous CVA
Ticagrelor 180mg if previous CVA and Aspirin 300mg
Anti-coagulated Discuss with PPCI team

PPCI – POSTER

Read more

End of life care in the Emergency Department

Why recognising dying matters

Recognising that someone may be approaching the end of their life can be difficult, particularly in the busy and sometimes unpredictable environment of the Emergency Department. We may meet people and families at a moment of profound distress, with little time to build a relationship or understand what matters most to them. It is understandable that these conversations feel daunting.

Yet recognising the possibility of dying creates an opportunity to offer the right care: to treat distress, consider reversible problems, explain uncertainty honestly and help patients and those close to them make informed choices. End of life care is not an alternative to good emergency medicine; it is part of it. Compassionate care remains active care.

Read more

Atrial Fibrillation/Flutter

Actions

It’s essential any Modifiable causes are treated, these include:

    • Haemodynamic stress: Valvular disease/Hypertension/LVD/Thrombus
    • Atrial ischemia: Ischaemic Heart Disease
    • Inflammation: Sepsis/Myocarditis/pericarditis
    • Noncardiovascular respiratory causes: PE/Pneumonia/Lung Cancer
    • Alcohol and drug use: Alcohol/Cocaine/Amphetamine
    • Endocrine disorders: Hyperthyroid/Diabetes/Phaeochromacytoma/Electrolyte prob.
    • Neurologic disorders: Subarachnoid Haemorrhage/Stroke
    • Genetic factors
    • Advancing age

Tests (NEW AF)

  • 12 Lead ECG
  • Bloods: FBC, U&E, Bone profile, Magnesium, LFT, TFT, Clotting, Glucose
  • Others: individualised to the patient.
  • First line:
    • β-Blocker – outperforms calcium channel blockers in studies
    • Non-dihydropyridine calcium channel blockers (Diltiazem/Verapamil) – esp. in Severe COPD/Asthma
  • Second Line:Consider adding in
    • Digoxin – however, digoxin alone is not effective in patients with increased sympathetic drive. Observational studies have associated digoxin use with excess mortality in AF patients)
    • Amiodarone can be useful as a last resort when heart rate cannot be controlled with combination therapy in patients who do not qualify for non-pharmacological rate control

Rhythm control in ED

“Early cardioversion is not recommended without appropriate anticoagulation or transoesophageal echocardiography if AF duration is longer than 24 h, or there is scope to wait for spontaneous cardioversion.”

In reality risks increase beyond 12hrs from onset, and those reverted in ED will often return to AF by the time they get to AF clinic follow up.

  • ESC/NICE recommends using the CHADS-VASc to assess stroke risk and ORBIT to assess bleeding risk
  • There are currently significant delays getting to “New AF” clinic as well as to GP’s, making assessment of Stroke risk in ED more important than ever

CHADS-VASc outcome recommendations

    • Males (0), Female (1) – No anticoagulation recommended
    • Males (1) – Consider anticoagulation (DOAC) in light of bleed risk
    • ALL (≥2) – Anticoagulation recommended (DOAC)- Trust DOAC guide,  NICE/CKS
    • Use Apixaban where first line, significantly cheaper. If using alternative please document reasons.

ORBIT outcome recommendations

    • Modifiable risks – Address ALL modifiable risk factors
    • Most will benefit from anticoagulation – but discuss personalised risk with patients

Contraindications to Anticoagulation inc:

    • Active serious bleeding (where the source should be identified and treated)
    • Associated comorbidities (e.g. severe thrombocytopenia <50 platelets/lL, severe anaemia under investigation, etc.)
    • Recent high-risk bleeding event such as intracranial haemorrhage (ICH).
  • Life Style
    • Obesity: Risk of AF, Recurrence of AF and Stoke all increase with BMI
    • Alcohol: Alcohol excess both increases the risk of AF and of Bleeding, so patient should support to reduce aldol intake is recommended
    • Caffeine: It is unlikely caffeine consumption causes AF. Habitual caffeine use may reduce the risk of developing AF. But increases the symptoms
    • Exercise: Moderate cardiavasclar exercise is protective, however higher rates of AF are seen in elite athletes and vigorous physical activity
  • Specific conditions- patient should follow up with GP/Clinic (treatment may start in ED)
    • Hypertension
    • Heart Failure
    • Coronary artery disease
    • Diabetes Mellitus
    • Sleep Apnoea

Arrhythmia clinic is for patients with newly diagnosed and symptomatic AF/SVT (if the patient is not symptomatic they should be followed up through their GP).

It should be remembered that patients will be seen after at least 6 weeks so anticoagulation decisions should not be delayed for clinic.

GUIDANCE

Based primarily on:

EMbeds clinical quick guide

Last evidence review: October 2026
Suggested next review: October 2026

This is a clinical support guide and does not replace clinical judgement, current CHFT medicines guidance or specialist advice.

Anaphylaxis 2021

Not all Allergies are Anaphylaxis!

Anaphylaxis is defined as:

  • Severe life-threatening systemic hypersensitivity reaction
  • Where BOTH of the following criteria are met:
    1. Sudden onset & rapid progression
    2. Life-threatening compromise of ONE or MORE of: Airway/Breathing/Circulation

Read more

Tachycardia

Adult ED Management – RCUK 2025

Treat the patient, not the rate

Sinus tachycardia is usually compensatory — identify and treat the cause. Do NOT cardiovert sinus tachycardia.


INITIAL ASSESSMENT

ABCDE

Cardiac monitor
BP and SpO₂
12-lead ECG
IV access
Bloods as clinically indicated: FBC
U&E / Mg²⁺ / Ca²⁺
glucose
troponin where indicated
other investigations directed by likely cause
Give oxygen only if SpO₂ <94%, unless an alternative target is appropriate.

Think WHY the patient is tachycardic?

Sepsis/Hypovolaemia/Haemorrhage
Pain/Anxiety
Hypoxia
Fever
PE
ACS/Heart failure
Thyrotoxicosis
Drugs/Withdrawal
Pregnancy

Do not attempt to normalise an appropriate sinus tachycardia with anti-arrhythmics or electrical cardioversion.


SIMPLE ED RULE

SICK? → SHOCK

WELL? → WIDTH + REGULARITY

  • Narrow + regular: Vagal → Adenosine → Verapamil / beta-blocker → Shock
  • Narrow + irregular: AF pathway / rate control
  • Broad + regular: VT until proven otherwise → Cardioversion / procainamide
  • Broad + irregular: Pre-excited AF / polymorphic VT → expert help

UNSTABLE?

LIFE-THREATENING FEATURES

> SHOCK: Hypotension with evidence of impaired tissue perfusion.
> SYNCOPE: Especially with severe or ongoing hypotension.
> MYOCARDIAL ISCHAEMIA: Ongoing chest pain and/or significant ischaemic ECG changes.
> SEVERE HEART FAILURE: Particularly pulmonary oedema.
> IMMEDIATELY POST-ROSC

DC-Cardiversion (SYNC) RCUK 2025

> AF → Maximum defibrillator output
> Flutter / SVT → 70–120 J
> VT with pulse → 120–150 J

Escalate subsequent shocks where appropriate.


STABLE

Regular  – Sinus Tachycardia, AVNRT (SVT), Atrial flutter with regular block, AVRT (WPW)

  • Sinus Tachycardia – Look for the cause ?infection ?pain ?anaemia ?hypovolaemia ?anxiety ?drugs
  • SVT – Stepwise treatment until NSR regained (ensure cardiac monitoring): –
    • Vagal Manoeuvres – Lie flat and head down, Carotid sinus massage (ensure no bruit 1st), Blow into 50ml syringe
    • Adenosine –  6mg, 12mg, 18mg boluses (not in severe Asthma/Allergy/Heart transplant)
    • Not reverted – call for expert help
  • Atrial Flutter with 2:1 block (150bpm) – consider rate controlling drugs
  • AVRT (WPW) – get expert help (DO NOT give Adenosine)

PDF: Arrhythmia Clinic referral form (Print and Fax OR can email – use fill and sign function to enter details)

PDF: Patient Info

Irregular – likely AF (Follow AF Pathway)

Assume VT until proven otherwise

Particularly in:

  • older patients
  • previous MI
  • structural heart disease
  • cardiomyopathy

Stable monomorphic VT

Electrical cardioversion is an appropriate first-line strategy

  • Especially where structural heart disease is present or cannot be excluded.
  • SYNCHRONISED CARDIOVERSION For VT with a pulse: 120–150 J initially, escalating if required

If sedation / anaesthesia presents significant risk

Drug treatment may be considered:

  • Procainamide 10–15 mg/kg IV over 20 minutes Maximum 1 g OR
  • Amiodarone 300 mg IV over 10–60 minutes followed by: 900 mg IV over 24 hours
  • If ineffective: SYNCHRONISED CARDIOVERSION WITH EXPERT ADVICE

STOP — HIGH-RISK RHYTHM

Consider:

  • 1. AF WITH BUNDLE BRANCH BLOCK
  • 2. PRE-EXCITED AF / WPW
  • 3. POLYMORPHIC VT

Seek senior / cardiology support early.


PRE-EXCITED AF

Think pre-excitation when there is:

  • very rapid irregular broad-complex tachycardia
  • varying QRS morphology
  • ventricular rates sometimes >200 bpm
  • known WPW / previous delta wave

DO NOT GIVE AV-NODAL BLOCKING DRUGS

Avoid the following as these may increase conduction through the accessory pathway and precipitate VF:

  • Adenosine
  • Beta-blockers
  • Verapamil
  • Diltiazem
  • Digoxin

Treatment

  • Procainamide OR
  • Synchronised cardioversion

If polymorphic VT occurs with QT prolongation:

Magnesium: Mg²⁺ 8 mmol IV over 10 minutes

Also:

  • Correct K⁺ / Mg²⁺ abnormalities.
  • Stop QT-prolonging drugs.
  • Treat reversible causes.
  • Seek expert help.

For recurrent pause-dependent torsades consider increasing the heart rate with:

  • Isoprenaline OR
  • Temporary pacing

❌ AVOID AMIODARONE because it may further prolong the QT interval.



⚠️ PITFALLS

FAST ≠ ARRHYTHMIA

Do not treat physiological sinus tachycardia as an arrhythmia.


BROAD + REGULAR = VT UNTIL PROVEN OTHERWISE

Do not delay appropriate treatment while attempting to prove SVT.


BROAD + IRREGULAR ≠ ROUTINE AF

Always consider pre-excited AF.


ADENOSINE IS NOT FOR IRREGULAR BROAD-COMPLEX TACHYCARDIA


DO NOT GIVE AMIODARONE FOR TORSADES / LONG-QT POLYMORPHIC VT

Give magnesium and correct the underlying problem.


CARDIOVERSION REQUIRES SYNC

Confirm the machine is marking the R waves before delivering the shock.

Re-check SYNC after each shock — some defibrillators automatically revert out of synchronised mode.


DISPOSITION

Consider admission / cardiology assessment for:

  • VT
  • broad-complex tachycardia of uncertain cause
  • syncope associated with tachyarrhythmia
  • significant structural heart disease
  • ACS / myocardial ischaemia
  • heart failure
  • recurrent arrhythmia despite treatment
  • pre-excitation
  • significant electrolyte disturbance
  • drug-induced arrhythmia
  • prolonged QT / torsades
  • haemodynamic instability
  • arrhythmia requiring electrical cardioversion

Patients with uncomplicated successfully terminated SVT may be suitable for discharge following senior review, appropriate investigation and follow-up depending on the clinical circumstances.


GUIDANCE

Based primarily on:

  • Resuscitation Council UK — Guidelines 2025: Adult Advanced Life Support
  • Resuscitation Council UK — Adult Tachyarrhythmia Algorithm, current version March 2026
  • Current atrial fibrillation guidance

EMbeds clinical quick guide

Last evidence review: September 2026
Suggested next review: September 2027

This is a clinical support guide and does not replace clinical judgement, current CHFT medicines guidance or specialist advice.

Early Pregnancy Pain & Bleeding

<16 WEEKS  (ED ALGORITHM)

1    INITIAL ASSESSMENT

Pain • bleeding • collapse • shoulder-tip pain • GI symptoms  →  THINK ECTOPIC
Complete: Urine pregnancy test  •  observations  •  stability  •  brief history + ectopic risk factors

2 ASSESS STABILITY

UNSTABLE

ABCDE
2 x IV cannulas
FBC/U&E/LFT/G&S ± crossmatch & serum β-hCG
Fluids/blood
URGENT GYNAE REVIEW
DO NOT transfer to EPAU before stabilisation.

STABLE

Discuss with EPAU – SAME DAY.
Then apply traffic-light triage below.

3    TRAFFIC-LIGHT TRIAGE

4   ED RULES

✓ DO

Urine pregnancy test
Assess stability
Consider ectopic
Discuss symptomatic patients with EPAU
Safety net

✕ DO NOT

Routinely request serum β-hCG in stable patients
Use β-hCG to decide scans
Promise scan times
Exclude ectopic because observations are normal

5   SAFETY NET

RETURN IMMEDIATELY to CRH

If: collapse, worsening pain, shoulder-tip pain, heavy bleeding, new symptoms, feeling unwell

KEY MESSAGE

Positive pregnancy test + pain/bleeding + NO confirmed intrauterine pregnancy
= ECTOPIC PREGNANCY REMAINS POSSIBLE UNTIL PROVEN OTHERWISE